DIPRIVAN (propofol) by Fresenius Kabi is action, like all general anesthetics, is poorly understood. Approved for general anesthetic [epc]. First approved in 1989.
Drug data last refreshed 11h ago · AI intelligence enriched 2w ago
DIPRIVAN (propofol) is a short-acting intravenous general anesthetic used for induction and maintenance of anesthesia across surgical and ICU settings. It works by positive modulation of GABA_A receptors to enhance inhibitory neurotransmission in the central nervous system. Propofol is a cornerstone agent in anesthesia practice with decades of clinical use.
Product is approaching loss of exclusivity with moderate competitive pressure (30/100), signaling transition from growth to mature/defensive market positioning requiring focus on retention and operational efficiency.
action, like all general anesthetics, is poorly understood. However, propofol is thought to produce its sedative/anesthetic effects by the positive modulation of the inhibitory function of the neurotransmitter GABA through the ligand-gated GABA A receptors.
General Anesthetic
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Propofol Dose-Finding for Colonoscope Insertion in Geriatric Patients
Efficacy and Safety of Fospropofol Disodium Versus Propofol for Deep Sedation in Critically Ill Patients
Comparison of Postoperative Recovery of Sevoflurane and Propofol After Transsphenoidal Surgery
Effect of Rematazolam Besylate, Propofol, and Sevoflurane Perioperative Sedation on Incidence of Emergence Agitation and Hemodynamics in Patients Undergoing Laparoscopic Abdominal Surgery
Efficacy and Safety of Remimazolam Besylate Versus Propofol for Sedation in Critically Ill Patients With Deep Sedation
Worked on DIPRIVAN at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moPositions linked to DIPRIVAN typically emphasize commercial execution, cost management, and market defense rather than innovation or launch activities. Careers on this product develop expertise in mature-market dynamics, generic competition, and operational efficiency within a stable but commoditized therapeutic class.